IBM, AMD, and the U.S. Department of Energy's Oak Ridge National Laboratory have introduced a new co-design platform that integrates quantum and high-performance classical computing to enhance quantum error correction. This collaboration aims to accelerate the development of fault-tolerant quantum computers, a key goal of the DOE's Quantum Genesis Mission targeting 100 logical qubits by 2028. The platform pairs IBM's 120-qubit Quantum Nighthawk with Oak Ridge's Umbra HPC system powered by AMD processors, enabling researchers to optimize error correction techniques and scale quantum computing capabilities. This initiative represents a significant step toward making quantum computing practical for scientific discovery and industry applications.
The collaboration between Oak Ridge National Laboratory, IBM, and AMD on a new quantum error correction platform is presented here with Pluang's Technology-sector market data as of Nov 05, 2026 19:32 WIB. Of 150 priced Technology-sector US stocks tradable on Pluang, 50 rose and 95 fell today. Notable movers include RELY at USD 23.99 with a 1-day change of -11.41% and 100% sell order activity, PAYC at USD 238.50 down 11.06%, and QCOM at USD 155.07 down 10.46%.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
